diabetes Archive — Page 3 of 17
-
July 10, 2023
Gannon receives career achievement award for islet biology research
Vanderbilt's Maureen Gannon, PhD, received the Paul Lacy Medal Award, the highest honor given by the Midwest Islet Club in recognition of meritorious career achievement in the field of islet biology. -
June 13, 2023
Maternal diet influences postnatal diabetes risk
Studies in a primate animal model suggest that islet hyperfunction — which in humans is associated with increased fat mass and Type 2 diabetes — is programmed in offspring by a maternal Western-style diet during pregnancy. -
May 23, 2023
Diabetes Day celebrates 50 years of achievement, spotlights current investigations
Vanderbilt Diabetes Day, an annual event hosted by the now-named Vanderbilt Diabetes Research and Training Center (DRTC). The event spotlights the work of researchers, and this year also celebrated the 50-year anniversary of the DRTC. -
May 19, 2023
Gorden honored with Vanderbilt Diabetes Center Lifetime Achievement Award
Phillip Gorden, MD, a Vanderbilt University undergraduate and School of Medicine alumnus, was recently honored with the Vanderbilt Diabetes Center Lifetime Achievement Award, during the recent Diabetes Day sponsored by the Vanderbilt Diabetes Research and Training Center and the Irwin B. Eskind Endowed Symposium. -
May 8, 2023
Diabetes drugs associated with fewer adverse cardiac events in older veterans: study
Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease. -
April 24, 2023
Kenneth Reynolds weighed 780 lbs., and his body was shutting down. Vanderbilt Weight Loss Center gave him back his life.
Coming up: going fishing with his grandchildren -
March 23, 2023
Study sheds light on drug’s impact on diabetes progression
A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.